Roche's Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and childrenGlobeNewsWire • 06/25/21
Genentech's Actemra Receives FDA Emergency Use Authorization for the Treatment of COVID-19 In Hospitalized Adults and ChildrenBusiness Wire • 06/24/21
FDA accepts application for Roche's Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD)GlobeNewsWire • 06/24/21
FDA Accepts Application for Genentech's Port Delivery System With Ranibizumab (PDS) for Treatment of Wet Age-Related Macular Degeneration (AMD)Business Wire • 06/24/21
Roche's Alzheimer's Antibody Reduces Associated Biomarkers In Subset Of AD Patients, Study ShowsBenzinga • 06/22/21
Roche SARS-CoV-2 molecular test granted first FDA Emergency Use Authorization for PCR testing of both symptomatic and asymptomatic individuals at the point of carePRNewsWire • 06/18/21
Roche data at EAN 2021 showcase significant impact of therapies across diverse neuroscience portfolioGlobeNewsWire • 06/15/21
Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemiaGlobeNewsWire • 06/11/21
Genentech Announces Data at EHA2021 Reinforcing Efficacy of Venclexta Combinations in Chronic Lymphocytic Leukemia and Acute Myeloid LeukemiaBusiness Wire • 06/11/21
New Roche data for Evrysdi show improved motor function in pre-symptomatic babies after one year and confirm safety profile in previously treated people with spinal muscular atrophy (SMA)GlobeNewsWire • 06/11/21
New Genentech Data for Evrysdi (risdiplam) Show Improved Motor Function in Pre-Symptomatic Babies After One Year and Confirm Safety Profile in Previously Treated People With Spinal Muscular Atrophy (SMA)Business Wire • 06/11/21
Roche obtains CE mark for the SARS-CoV-2 Antigen Self Test Nasal allowing for rapid self testing of COVID-19 at homeGlobeNewsWire • 06/08/21
Genentech Presents Latest Advances With Immunotherapies in Non-Hodgkin's LymphomaBusiness Wire • 06/04/21
AbbVie-Roche Win European Approval for Venclyxto in Newly Diagnosed Acute Myeloid LeukemiaBenzinga • 05/25/21
European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapyGlobeNewsWire • 05/25/21